Novo Nordisk's Summer of Contradictions: Buybacks, Lower Doses, and a Pipeline That Can't Afford Another Miss

Novo Nordisk spends billions on buybacks while testing lower Wegovy doses to boost tolerability, facing Lilly competition and mixed trial results.

There is a peculiar tension at the heart of Novo Nordisk's current strategy. The Danish pharma giant is simultaneously funneling billions into its own shares while fine-tuning the dosage of its flagship obesity pill down to the smallest effective strength. One move signals confidence in the stock; the other signals a company fighting hard for every incremental patient in an increasingly crowded market.

The numbers behind the buyback are striking. Since February 4, Novo Nordisk has repurchased nearly 28.9 million B-shares at an average price of 279.80 Danish kroner, for a total outlay of roughly 8.08 billion kroner. The program, which carries a 15 billion kroner ceiling, had already consumed more than half its budget by August 14. Management's message is clear: they believe the equity is undervalued. But as any analyst will point out, a buyback cannot buy pipeline success — it can only buy time.

Time, however, is precisely what the company needs as it navigates one of the most consequential stretches in its recent history. On August 12, Novo Nordisk launched OASIS-5, a Phase 3 trial testing lower maintenance doses of the oral Wegovy pill in 450 adults with obesity or overweight. The study, which runs until 2028, aims to identify the lowest effective dose that maintains weight loss while improving tolerability. In a therapeutic category where gastrointestinal side effects drive patients to abandon treatment within months, a well-calibrated minimum dose could be the difference between a blockbuster and a drug that underwhelms.

The dosing strategy reflects a broader philosophical bet. CEO Mike Doustdar argued in mid-August that investors are underestimating demand for differentiated obesity medicines. He reaffirmed plans to bring CagriSema to market next year, even though the candidate trailed Eli Lilly's Zepbound on weight-loss efficacy in clinical trials. The wager is not on the strongest effect, but on the full package: tolerability, market access, and brand trust.

Diabetes remains the quieter engine of the story. Early August saw the U.S. launch of Awiqli, which Novo Nordisk describes as the first once-weekly basal insulin for adults with type 2 diabetes, following FDA approval. The product tackles the same compliance challenge that underpins the obesity pill strategy — less frequent administration, better adherence. A partnership with AWS to accelerate drug discovery through artificial intelligence adds a technological layer to the innovation push, a reminder that the competitive clock against Lilly never stops ticking.

Yet the summer has delivered a decidedly mixed scorecard. Positive Phase IIIa data for oral semaglutide in adolescents with type 2 diabetes showed a statistically significant HbA1c reduction of 0.83 percentage points versus placebo, with regulatory filings in the U.S. and EU planned for the second half of 2026. But the cardiovascular SUSE trial for Ziltivekimab missed its primary endpoint, with a hazard ratio of 0.99 for major adverse cardiovascular events — effectively no difference from placebo. That failure compounds the already-booked $4 billion impairment on Monlunabant, and Morningstar, in its mid-August assessment, labeled 2026 a "trough" year, trimming its fair value estimate for the B-shares to 285 Danish kroner on generic competition and margin-eroding cash-pay offerings.

The stock itself sits in a technical limbo. Friday's close of 39.98 euros marked a 1.0 percent daily gain and a 1.6 percent weekly advance — modest green shoots, but the share remains roughly 70 percent below its mid-2024 peak, with the 52-week high of 54.86 euros a distant memory. The shares trade just under the 200-day moving average and about 3.9 percent below the 50-day average, while 30-day volatility of 40 percent speaks to persistent nervousness. A recent legal victory in The Hague, which barred a Dutch pharmacy from producing and selling unapproved semaglutide nasal sprays, offers some protection against copycat products, but it does little to address the core pressure from cheaper cash-pay alternatives and generic semaglutide in markets like Canada and Brazil.

The company's own guidance — raised last month to 0 to 6 percent operating growth for the year — implicitly acknowledges the earnings decline ahead. Every pipeline readout between now and the second-half 2026 regulatory submissions for oral semaglutide in adolescents will be judged against that single question: can new indications and formulations offset the erosion in the core business? The next concrete milestones are the progress of OASIS-5 and those regulatory filings. Both will determine whether Novo Nordisk can engineer its turnaround from within — or whether the buyback program ends up as little more than a footnote to a more difficult story.